Brief: TScan Therapeutics Q2 Net Income USD -31.661 Million
12/08/2024 12:00
Aug 12 (Reuters) - TScan Therapeutics Q2 basic EPS USD -0.28. * Q2 operating expenses USD 34.65 million * Q2 collaboration and license revenue USD 536 thousand * Q2 income from operations USD -34.114 million
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing